Palatin Technologies, Inc. (AMEX: PTN), a biopharmaceutical company, has dedicated their efforts to developing peptide, peptide mimetic and small molecule agonist compounds. Their primary focus is on melanocortin and natriuretic peptide receptor systems, including acute hospital care products in the cardiovascular field, for treating congestive heart failure, hard-to-control hypertension as well as cardiac surgery organ protection. For further information, visit the Company’s web site at www.palatin.com.
- 17 years ago
QualityStocks
Palatin Technologies, Inc. (AMEX: PTN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation
NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharma company, has filed a patent application for NRX-100,…
-
ZDKL Champions World Peace Through Trade with Decentralized Tools for Global Commerce
Investor Brand Network ZDKL, a regulation-first blockchain project, has officially launched the Peace Through Trade…
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Ramps Up Innovation, Logistics to Power Growth
Massimo (NASDAQ: MAMO) is making strategic moves to actively enhance its position in the powersports and…